SCHEMBL1462341

SCHEMBL1462341

O=C(Cl)c1ccnc(Cl)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
ASPH Q12797 1/20 0.44
KDM8 Q8N371 1/20 0.44
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 1/20 0.41
EGFR P00533 1/20 0.35
ATR Q13535 1/20 0.35
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
NAPRT Q6XQN6 1/20 0.33
KMO O15229 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418893 0.84 KDM4E (0.63) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL473869 0.84 KDM4E (0.63) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL23326783 0.82 KDM4E (0.43) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL27096669 0.82 KDM4E (0.43) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL22466559 0.82 KDM4E (0.46) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL27189436 0.82 KDM4E (0.46) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL27471803 0.79 SMN1; SMN2 (0.44) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL1031057 0.79 SMN1; SMN2 (0.44) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL29209717 0.78 KDM4E (0.43) KDM4EASPHKDM8SMN1; SMN2ALDH1A1
SCHEMBL30881744 0.78 KDM4E (0.43) KDM4EASPHKDM8SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897842-B1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2025-01-29 EP disclosed
CN-113490527-B Bicyclic derivatives 瑞士伊兰科动物保健有限公司 2024-10-25 CN disclosed
US-20220064159-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2022-03-03 US disclosed
EP-3897842-A1 BICYCLIC DERIVATIVES Elanco Tiergesundheit AG (CH) 2021-10-27 EP disclosed
CN-113490527-A Bicyclic derivatives 瑞士伊兰科动物保健有限公司 2021-10-08 CN disclosed
WO-2020131631-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2020-06-25 WO disclosed
US-20130018033-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2013-01-17 US disclosed
EP-2493865-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-09-05 EP disclosed
WO-2011025938-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064159-A1 BICYCLIC DERIVATIVES FABP3, CYCS, PIGS KDM4E 2222/4885ASPH 3442/4885KDM8 2797/4885
US-20130018033-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF KDM4E 3645/4885ASPH 1825/4885KDM8 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.